The current financial score of Puma Biotechnology Inc is 8.43. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 56.50M, representing a year-over-year increase of 7.75%, while its net profit experienced a year-over-year increase of 39.86%.
The current valuation score of Puma Biotechnology Inc is 7.39. Its current P/E ratio is 20.11, which is 599098.42% below the recent high of 120500.00 and 432.43% above the recent low of -66.85.
The current earnings forecast score of Puma Biotechnology Inc is 6.00. The average price target is 6.00, with a high of 6.00 and a low of 6.00.
The current price momentum score of Puma Biotechnology Inc is 3.58. Currently, the stock price is trading between the resistance level at 10.27 and the support level at 9.07, making it suitable for range-bound swing trading.
The current institutional shareholding score of Puma Biotechnology Inc is 7.00. The latest institutional shareholding proportion is 81.56%, representing a quarter-over-quarter increase of 14.60%. The largest institutional shareholder is James Simons, holding a total of 1.84M shares, representing 0.02% of shares outstanding, with 150.24% increase in holdings.
The current risk assessment score of Puma Biotechnology Inc is 6.14. The company's beta value is 1.21. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.